WCC Biomedical announced an remarkable achievement as its next-generation pain-relief product WCC-301 successfully completed the US FDA Pre-IND meeting and has now entered GLP toxicology studies, marking a major step toward Phase I/IIa clinical trials next year. Meeting US FDA’s large-scale batch manufacturing requirements demonstrates that WCC’s microarray platform has reached a level of high uniformity, reproducibility, and true mass-production capability—a standard many global competitors have not been able to achieve.
Powered by the proprietary WINMAP™ microarray platform, WCC-301 delivers pain relief within 5–15 minutes, significantly faster than conventional patches that require 4–6 hours. With zero gastrointestinal side effects, the product aims to redefine pain-management standards and tap into the US$10B global pain-relief market, with licensing discussions ongoing with several major pharmaceutical companies—including a leading Japanese transdermal drug maker. The Asia-Pacific licensing opportunity is estimated to exceed US$300M.
In addition, WCC Biomedical became the only Taiwanese microarray company invited by BARDA to the Vaccine Innovation Forum, showcasing its mRNA microarray vaccine delivery technology recognized for improving stability, reducing cold-chain needs, and enabling self-administration. This international recognition further validates WCC’s precision microarray engineering and scalable manufacturing excellence.
With clinical development progressing and strong commercial interest, WCC is preparing to enter the capital market next year via an emerging-stock listing and public offering, aiming to accelerate global commercialization and strengthen Taiwan’s position in microarray innovation.
“From Taiwan to the world — redefining drug delivery through precision microarray technology,” said Dr. Liu Dajiao, Chairman of WCC Biomedical.